SCHEMBL25439804

SCHEMBL25439804

COC(=O)c1cc(-c2ccn3nc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)nc3c2)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TDP2 O95551 4/20 0.37
CSNK2A1 P68400 2/20 0.36
MEN1 O00255 3/20 0.36
LMNA P02545 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SYK P43405 1/20 0.35
SUV39H2 Q9H5I1 2/20 0.34
PFKFB3 Q16875 1/20 0.33
ATR Q13535 1/20 0.33
NR1I2 O75469 1/20 0.33
NR1I3 Q14994 1/20 0.33
PDK2 Q15119 1/20 0.32
NOTUM Q6P988 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25439816 0.84 CSNK2A1 (0.35) TSHRALDH1A1TDP2CSNK2A1SMN1; SMN2
SCHEMBL31489228 0.82 TDP2 (0.32) TDP2SUV39H2
SCHEMBL25439782 0.82 TDP2 (0.48) TDP2MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL25439950 0.80 CSNK2A1 (0.38) ALDH1A1CSNK2A1SMN1; SMN2KDM4E
SCHEMBL20472618 0.80 CSNK2A2 (0.33) TSHRALDH1A1TDP2CSNK2A1MEN1
SCHEMBL31489435 0.78 PIK3CG (0.33) TDP2LMNAKMT2ASYKSUV39H2
SCHEMBL25439870 0.78 PIK3CG (0.46) TSHRALDH1A1TDP2MEN1LMNA
SCHEMBL31507885 0.78 TDP2 (0.31) TDP2CSNK2A1
SCHEMBL31489548 0.77 TDP2 (0.35) ALDH1A1TDP2SMN1; SMN2KDM4ESUV39H2
SCHEMBL29786533 0.77 PLA2G2A (0.51) TSHRALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364737-A2 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2024-05-08 EP disclosed
EP-4229056-B1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-10 EP disclosed
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-04 US disclosed
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 TSHR 3292/4885ALDH1A1 4270/4885TDP2 1113/4885
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors RIPK1, RIPK3, RIPK4 TSHR 3292/4885ALDH1A1 4270/4885TDP2 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.